|
|
 |
| |
|
Home > Drug Companies > Berlex Laboratories
Berlex Laboratories
Berlex entered the US market in 1979 by acquiring certain assets of the Internal Medicine division of Cooper Laboratories, in New Jersey. This acquisition provided Schering AG Germany, Berlex's parent company with expertise in cardiovascular disease. It also provided it with a platform for launching female healthcare and diagnostic imaging products.
In 1990, Berlex expanded into biotechnology with the acquisition of Codon and certain assets of Triton Biosciences, both located in the San Francisco area. By 1993, all Berlex research was consolidated in Richmond, California. In 2002, Berlex acquired Leukine and established operations in Washington State to support its oncology business and clinical development programs.
The Company since 1980, Berlex has enjoyed a compound sales growth of 17 percent and has had a history of impressive firsts Magnevist, Fludara¸ Betaseron, Climara, and Yasmin. In the U.S, Berlex's singular approach to developing and making specialized medicines already has yielded innovations in treating multiple sclerosis, dermatological disorders, female health concerns, cancer and in the creation of new diagnostic imaging techniques. For the future, the pipeline of new products and the potential for developing better treatments will help make medicine work for those who need it most in the years ahead.
Berlex Laboratories, this company in the health care business is only as good as the products it makes and the value it provides those who use its products patients, their caregivers and health care providers including physicians, nurses, pharmacists, technicians and health maintenance organizations.
There are three ways you can locate information about their products. All Products will allow you to find a product by name, products by condition will allow you to view which of their products treat a condition or disease and products by business area divide their products into larger therapeutic areas. Berlex's singular approach to developing and making specialized medicines already has yielded innovations in treating multiple sclerosis, female health concerns, cancer and in the creation of new diagnostic imaging techniques.
The Company clinical research team works with patients and physicians to evaluate safety, delivery methods and efficacy of their products. In the end, elegant science their drive toward perfection, refinement and full understanding of minute disease processes brings to market medicines that, like a home, can give comfort, increase their sense of well being or security, and improve or sustain their quality of life. Simply put, making medicines that work.
Back to Drug Companies
|
|
|
|
|
|
|
|